In a historical move, healthcare investor giant Deerfield Management entered a second partnership with one of its academic collaborators, investing up to $130 million over the next ten years into Dana-Farber Cancer Institute to advance the development of new therapeutics and diagnostic tools for cancer patients.

A first-of-its-kind investing collaboration is combining MPM Capital’s venture capital investment fundraising with Dana-Farber Cancer Institute’s philanthropic fundraising for cancer research.

A Phase III trial is planned after promising results were revealed from Dana-Farber Cancer Institute for MK-6482 in advanced clear cell kidney cancer.

A new blood test in development from GRAIL Inc. and studied by investigators at the Dana-Farber Cancer Institute has the ability to accurately screen for numerous types of cancer.